APA (7th ed.) Citation

Higaki, H., Nishioka, K., Otsuka, M., Nishikawa, N., Shido, M., Minatogawa, H., . . . Nishiyama, N. (2023). Brain metastases in Japanese NSCLC patients: Prognostic assessment and the use of osimertinib and immune checkpoint inhibitors—retrospective study. Radiation Oncology, 18(1), 1. https://doi.org/10.1186/s13014-023-02218-3

Chicago Style (17th ed.) Citation

Higaki, Hajime, et al. "Brain Metastases in Japanese NSCLC Patients: Prognostic Assessment and the Use of Osimertinib and Immune Checkpoint Inhibitors—retrospective Study." Radiation Oncology 18, no. 1 (2023): 1. https://doi.org/10.1186/s13014-023-02218-3.

MLA (9th ed.) Citation

Higaki, Hajime, et al. "Brain Metastases in Japanese NSCLC Patients: Prognostic Assessment and the Use of Osimertinib and Immune Checkpoint Inhibitors—retrospective Study." Radiation Oncology, vol. 18, no. 1, 2023, p. 1, https://doi.org/10.1186/s13014-023-02218-3.